NBP-14 and derivatives
Diabetic Retinopathy
ResearchActive
Key Facts
About Neuro Bio
Neuro Bio is a private, preclinical-stage biotech pioneering a disruptive hypothesis for Alzheimer's disease (AD) that challenges the dominant amyloid dogma. The company's core discovery is the T14 peptide, which it posits triggers an aberrant, developmental-like process in specific vulnerable neurons, driving neurodegeneration upstream of amyloid plaque formation. This mechanism informs a dual strategy: a diagnostic pipeline for early detection of T14 in nasal secretions and saliva, and a therapeutic pipeline led by NBP-14, an antagonist of T14. The company is also exploring applications of its platform in oncology, dermatology, and diabetic retinopathy, indicating a broader platform potential.
View full company profileOther Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (DR) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| NOX4 Inhibitor (GLX7013114) | Glucox Biotech | Preclinical |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| jCell (RPCs) | jCyte | Preclinical |
| LumineticsCore | Digital Diagnostics | Approved |
| Diabetic Retinopathy Program | Lxbio Pharmaceuticals | Pre-clinical |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical |
| Vasculogenic Cell Therapy | Vascugen | Pre-clinical |
| Danegaptide | Breye Therapeutics | Phase 2 |
| OcuRetina | Oculotix | Phase 2 |
| YH14618 | Yuhan | Phase 2 |